Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 23, Issue 2, 2005, Pages 93-101

  Safarinejad, Mohammad Reza ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Docetaxel; Drug therapy; Estramustine; Prostatic neoplasms; Suramin

Indexed keywords

AMINOTRANSFERASE; BILIRUBIN; COLONY STIMULATING FACTOR; CREATININE; DOCETAXEL; ESTRAMUSTINE; PROSTATE SPECIFIC ANTIGEN; SURAMIN;

ADULT; AGED; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BILIRUBIN BLOOD LEVEL; BLOOD TRANSFUSION; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; HYPONATREMIA; KIDNEY FAILURE; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FAILURE; MALAISE; MALE; NAUSEA; NEUROPATHY; PAIN ASSESSMENT; PERIPHERAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RASH; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; TUMOR VOLUME; UREA NITROGEN BLOOD LEVEL; VOMITING;

EID: 18144369269     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2004.10.003     Document Type: Article

References (30)

1. D.M. Savarese, S. Halabi, V. Hars Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B J Clin Oncol 19 2001 2509 2516
2. B. Hartley-Asp, P. Gunnarson growth and cell survival following treatment with estramustine, nor-nitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line (DU-145) J Urol 17 1982 818 822
3. B. Hartley-Asp Estramustine-induced mitotic arrest in tow human prostatic carcinoma cell lines DU-145 and PC-3 The Prostate 5 1984 93 100
4. F. Lavelle, M.C. Bissery, C. Combeau Preclinical evaluation of docetaxel (Taxotere) Semin Oncol 22 suppl. 4 1995 3 16
5. S. Haldar, A. Basu, C. Croce Bcl-2 is the guardian of microtubule integrity Cancer Res 57 1997 229 233
6. R.C. Benson, B. Hartley-Asp Mechanisms of action and clinical uses of estramustine Cancer Invest 8 1990 375 382
7. G.R. Hudes, F.E. Nathan, C. Khater Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer Sem Oncol 22 1995 41 46
8. G.R. Hudes, F.E. Nathan, C. Khater Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer J Clin Oncol 15 1997 3156 3161
9. L. Speicher, N. Liang, L. Barone Interaction of an estramustine photoaffinity analogue with cytoskeletal proteins in prostate carcinoma cells Molecular Pharmacol 46 1994 8866 8872
10. W. Kreis, D. Budman, A. Calabro Unique synergism or antagonism of combination of chemotherapeutic and hormonal agents in human prostate cancer cell lines Br J Urol 79 1997 196 202
11. C. Mahler, L. Denis Treatment of hormone refractory disease Semin Surg Oncol 11 1995 770 783
12. M.A. Eisenberger, V.J. Sinibaldi, L.M. Reyno Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with metastatic hormone-refractory prostate cancer J Clin Oncol 13 1995 2174 2186
13. C. Myers, M. Cooper, C. Stein Suramin a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer J Clin Oncol 10 1992 881 889
14. S.J. Eric, M. Mark, M.M. Ernest Suramin therapy for patients with symptomatic hormone-refractory prostate cancer results of a randomized phase iii trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone J Clin Oncol 18 2000 1440 1450
15. C.S. Cleeland, K.M. Tyan Pain assessment global use of the brief Pain Inventory Ann Acad Med Singapore 23 1994 129 138
16. E.A. Gehan The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent J Chronic Dis 13 1961 346 353
17. J.R. Anderson, K.C. Cain, R.D. Gelber Analysis of survival by tumor response J Clin Oncol 1 1989 710 719
18. E.J. Small, A. McMillan, M. Meyer Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients association with progression-free survival, pain end points, and survival J Clin Oncol 19 2001 1304 1311
19. P. Kantoff, S. Halabi, M. Conaway hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer the results of CALGB 9182 J Clin Oncol 7 1999 2506 2513
20. S. Culine, J.P. Droz Chemotherapy in advanced androgen-independent prostate cancer 1990-1999 a decade of progress? Ann Oncol 11 2000 1523 1528
21. D. Petrylak, G. Shelton, C. England-Owen Response and preliminary survival results of a phase II study of docetaxel (D) and estramustine (E) in patients (Pts) with androgen-independent prostate cancer Proc Am Soc Clin Oncol 19 2000 334a
22. J. Picus, M. Schultz Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer preliminary results Semin Oncol 26 1999 14 18
23. D. Friedland, J. Cohen, R. Miller A phase II trial of Docetaxel (Taxotere) in hormone-refractory prostate cancer correlation of antitumor effect to phosphorylation of Bcl-2 Semin Oncol 26 1999 19 23
24. K.J. Pienta, B.G. Redman, R. Bandekar A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer Urology 50 1997 401 407
25. A.L. Weitzman, G. Shelton, N. Zuech Dexamethasone dose not significantly contributes to the response rate of docetaxel and estramustine in androgen independent prostate cancer J Urol 163 2000 834 839
26. S. Urakami, M. Igawa, N. Kikuno Combination chemotherapy with paclitaxel, estramustine, and carboplatin for hormone-refractory prostate cancer J Urol 168 2002 2444 2450
27. R. Amato, J. Ellerhorst, A. Sella Estramustine and vinblastine for patients with progressive androgen independent adenocarcinoma of the prostate Urol Oncol 1 1995 165 172
28. W. Kreis, D. Budman, J. Fetten Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone-refractory prostate carcinoma Ann Oncol 10 1999 33 38
29. V. Sinibaldi, M. Carducci, S. Moore-Cooper A phase II study evaluating docetaxel (D) and one day of estramustine phosphate (EMP) in patients (Pts) with hormone refractory prostate cancer (HRPC) updated preliminary analysis Proc Am Soc Clin Oncol 19 2000 346a
30. R. Natale, S. Zaretsky Phase I/II trial of estramustine and Taxotere in patients with metastatic hormone-refractory prostate cancer Proc Am Soc Clin Oncol 18 1999 348a